Stock Analysis

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb

The KPS Corporation (KOSDAQ:256940) share price has done very well over the last month, posting an excellent gain of 33%. Taking a wider view, although not as strong as the last month, the full year gain of 24% is also fairly reasonable.

Although its price has surged higher, there still wouldn't be many who think KPS' price-to-sales (or "P/S") ratio of 1.1x is worth a mention when the median P/S in Korea's Semiconductor industry is similar at about 1.2x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

See our latest analysis for KPS

ps-multiple-vs-industry
KOSDAQ:A256940 Price to Sales Ratio vs Industry February 6th 2025
Advertisement

How Has KPS Performed Recently?

With revenue growth that's exceedingly strong of late, KPS has been doing very well. The P/S is probably moderate because investors think this strong revenue growth might not be enough to outperform the broader industry in the near future. If that doesn't eventuate, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.

Although there are no analyst estimates available for KPS, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.

Is There Some Revenue Growth Forecasted For KPS?

In order to justify its P/S ratio, KPS would need to produce growth that's similar to the industry.

Retrospectively, the last year delivered an exceptional 91% gain to the company's top line. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.

This is in contrast to the rest of the industry, which is expected to grow by 41% over the next year, materially lower than the company's recent medium-term annualised growth rates.

With this information, we find it interesting that KPS is trading at a fairly similar P/S compared to the industry. It may be that most investors are not convinced the company can maintain its recent growth rates.

The Bottom Line On KPS' P/S

KPS' stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

We didn't quite envision KPS' P/S sitting in line with the wider industry, considering the revenue growth over the last three-year is higher than the current industry outlook. It'd be fair to assume that potential risks the company faces could be the contributing factor to the lower than expected P/S. At least the risk of a price drop looks to be subdued if recent medium-term revenue trends continue, but investors seem to think future revenue could see some volatility.

Don't forget that there may be other risks. For instance, we've identified 1 warning sign for KPS that you should be aware of.

Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Valuation is complex, but we're here to simplify it.

Discover if Keeps Biopharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSDAQ:A256940

Keeps Biopharma

Engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally.

Mediocre balance sheet and slightly overvalued.

Advertisement

Updated Narratives

CE
CEG logo
cementafriend on Constellation Energy ·

Constellation Energy Dividends and Growth

Fair Value:US$348.054.7% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KH
CRWV logo
Khagani on CoreWeave ·

CoreWeave's Revenue Expected to Rocket 77.88% in 5-Year Forecast

Fair Value:US$11033.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PO
BIS logo
PortfolioPlus on Bisalloy Steel Group ·

Bisalloy Steel Group will shine with a projected profit margin increase of 12.8%

Fair Value:AU$6.7118.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
101 users have followed this narrative
10 users have commented on this narrative
20 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.3% undervalued
935 users have followed this narrative
6 users have commented on this narrative
23 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.8% undervalued
140 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative